| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_053ae1db1da7cfd3029bfdce4f71349f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47c4e10f683de95378a70f0b3daebad9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7a4229c8f9c1356befe9e5d5a0f8c32 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-422
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N45-00 |
| filingDate |
2009-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b98d700f551e8008df075bbfd6e7dc9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_258acc033970de37bcc65eed1e540696 |
| publicationDate |
2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010033637-A1 |
| titleOfInvention |
Dissolution of arterial plaque |
| abstract |
Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations. In some embodiments, pharmaceutical formulations include a combination of a bile acid and a terpene in amounts effective to result in plaque regression, and the amount of each individual emulsifier in the combination can be lower than an amount that is effective to result in plaque regression when the emulsifier is administered alone. In some embodiments, a statin can be administered simultaneously or sequentially with the pharmaceutical formulation. |
| priorityDate |
2008-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |